

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- ✓ • BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**




Figure 2A






Figure 2B





Promoterless	CMV Promoter	Integration Site
<u>Luc Activity</u>	<u>Luc Activity</u>	<u>Interpretation</u>
High	High	Nearby strong promoter
Low	Low	Nearby silencing element
Low	High	"Neutral" site

**Figure 3**

Figure 4A




Figure 4B






Figure 4C





**Figure 5**




Figure 6




Figure 7A





Figure 7B





**Figure 8**




Figure 9A




Figure 9B




Figure 10




Figure 11




Figure 12



Figure 13.





Figure 14.



# MLL Leukemia Cell Line TS(4;11) Treated with FLT3 Inhibitor PKC-412




FIG. 15



# MLL Leukemia Treated with FLT3 Inhibitor PKC-412




FIG. 16

# Validation of FLT3 as a Target in MLL




FIG. 17

# Validation of FLT3 as a Target in MLL Utilizing shRNA and *In Vivo* Imaging




FIG. 18

# ADW Effects in an Orthotopic Model of Multiple Myeloma (MM1S)




FIG. 19

# ADW Effects in an Orthotopic Model of Multiple Myeloma




FIG. 20

# Efficacy of AMN107 Against 32D/p210-Luc Cells *In Vivo*




FIG. 21

# Quantitation of AMN107 Effects Against 32D/p210-Luc Cells *In Vivo*




FIG. 22

# Orthotopic Brain Tumor Model




FIG. 23



# *In Vivo* Efficacy of AMD-3100




FIG. 24

# *In Vivo* Imaging of Transcriptional Pathway Activity




FIG. 25

# CXCR4 Inhibition with AMD3100 Attenuates ERK1/2 Signalling *In Vivo*




FIG. 26

# *In Vivo* Imaging of Hypoxia-Inducible Reporter Activity

Cell line: HepG2 Epo-Luc c.1  
Innoculum: 3 million cells  
Time: 48 hrs after implantation



FIG. 27